Aytu BioPharma's EPS (Basic) for the
three
months ended in Dec. 2023 was $-0.04.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.04.
During the past 3 years, the average EPS without NRIGrowth Rate was 61.60% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 71.70% per year.
During the past 13 years, Aytu BioPharma's highest 3-Year average EPS without NRI Growth Rate was 92.20% per year. The lowest was -11.50% per year. And the median was 61.65% per year.
Aytu BioPharma Earnings per Share (Diluted) Historical Data
The historical data trend for Aytu BioPharma's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aytu BioPharma's Earnings per Share (Diluted)
For the Drug Manufacturers - Specialty & Generic subindustry, Aytu BioPharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aytu BioPharma's PE Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aytu BioPharma's PE Ratio distribution charts can be found below:
* The bar in red indicates where Aytu BioPharma's PE Ratio falls into.
Aytu BioPharma Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Aytu BioPharma's Earnings Per Share (Diluted) for the fiscal year that ended in Jun. 2023 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.04
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
Aytu BioPharma (NAS:AYTU) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Aytu BioPharma Earnings per Share (Diluted) Related Terms
Thank you for viewing the detailed overview of Aytu BioPharma's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Aytu BioPharma (Aytu BioPharma) Business Description
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AYTU has been successfully added to your 